SVR12 in Genotype 3 HCV (F0-F2) Treated With RDV + SOF

This study will follow a group of people with chronic hepatitis C infection of genotype 3 who have mild to moderate liver fibrosis (stages F0-F2, measured by a liver stiffness test). All participants will be receiving the antiviral drugs ravidasvir and sofosbuvir as part of their regular medical care. Only patients who start this treatment, meet the study's eligibility criteria, and give written consent for their medical data to be used in research will take part. They will be monitored during their routine clinic visits while receiving the two-drug therapy. After 8 weeks of treatment, researchers will check how many patients have cleared the virus from their blood. Those who achieve this response will continue to be followed for another 4 and 12 weeks after treatment to see if the virus remains undetectable.

NCT Number	NCT07316842
Lead Sponsor	Center of target therapy
Conditions	Viral Hepatitis C
Enrollment	30 participants
Start Date	2025-09-17
Primary Completion	2026-02-02 (estimated)
Study Completion	2026-02-02 (estimated)
Updated on ClinicalTrials.gov	2026-01-05